Biocon Q1 performance to remain in focus

Biocon is declaring its April-June quarter performance on Thursday. Analysts expect consolidated net profit to grow 27-32 per cent year-on-year to ₹110-135 crore. Consolidated revenue is seen growing 20 per cent at ₹830 crore. The management had indicated in the annual report a greater investment in R&D, enhance operating efficiencies with a focus on product launches and licensing opportunities. Developments on those front will remain in focus.